

Sjögren's Syndrome—Study of Autoantigens and Autoantibodies

John G. Routsias · Athanasios G. Tzioufas

Published online: 26 September 2007
© Humana Press Inc. 2007

Abstract The presence of autoantibodies is the hallmark of systemic autoimmune diseases. During the past 30 years, intense clinical and basic research have dissected the clinical value of autoantibodies in many autoimmune diseases and offered new insights into a better understanding of the molecular and functional properties of the targeted autoantigens. Unraveling the immunologic mechanisms underlying the autoimmune tissue injury, provided useful conclusions on the generation of autoantibodies and the perpetuation of the autoimmune response. Primary Sjögren's syndrome (pSS) is characterized by the presence of autoantibodies binding on a vast array of organ and non-organ specific autoantigens. The most common autoantibodies are those targeting the Ro/La RNP complex, and they serve as disease markers, as they are included in the European–American Diagnostic Criteria for pSS. Other autoantibodies are associated with particular disease manifestations, such as anti-centromere antibodies with Raynaud's phenomenon, anti-carbonic anhydrase II with distal renal tubular acidosis, anti-mitochondrial antibodies with liver pathology, and cryoglobulins with the evolution to non-Hodgkin's lymphoma. Finally, autoantibodies against autoantigens such as alpha- and beta-fodrin, islet cell autoantigen, poly(ADP)ribose polymerase (PARP), NuMA, Golgins, and NOR-90 are found in a subpopulation of SS patients without disease specificity, and their utility remains to be elucidated. In this review, the molecular and clinical characteristics (divided according to their clinical utility) of the autoantigens and autoantibodies associated with pSS are discussed.

Keywords Sjogren's syndrome · Autoantigens · Ro(SS-A) · La(SS-B) · Carbonic anhydrase · Fodrin · Poly(ADP)ribose polymerase · Muscarinic receptor

Introduction

Sjögren's syndrome (SS) is a chronic autoimmune disease, characterized by the presence of a variety of autoantibodies directed against organ and non-organ specific autoantigens. Antinuclear antibodies (ANA), detected by immunofluorescence using Hep-2 cells, are present in the sera of 90% of patients. The most common of them are directed against two ribonucleoprotein antigens known as Ro or SSA and La or SSB. These autoantibodies are included in the European–American Diagnostic Criteria for Sjögren's Syndrome [1], but they can be also found in other autoimmune diseases, particularly systemic lupus erythematosus (SLE). High titer of antibodies to other immunoglobulins (known as rheumatoid factors) are also frequently found in SS. Apart from antibodies against salivary glands—found rather infrequently and in low titers—primary SS (pSS) sera contain many different autoantibodies against organ or tissue specific autoantigens, including acetylcholine receptors, the carbonic anhydrase and thyroid peroxidase. Finally, new autoantibodies directed against the cytoskeletal protein β -fodrin, and the muscarinic receptors M3, have also been described in primary Sjögren's syndrome.

During the last years, the pathogenetic mechanisms and the clinical utility of autoantibodies in pSS have been explored in detail [2]. Thus, it is now appreciated that the production of autoantibodies is an antigen-driven immune response, as (1) certain autoantibodies are disease specific, (2) contain multiple epitopes, and (3) the autoimmune response is perpetuated and augmented via intra- and in-

J. G. Routsias · A. G. Tzioufas (✉)
Department of Pathophysiology, Medical School,
National University of Athens,
M.Asias 75, 11527 Athens, Greece
e-mail: agtzi@med.uoa.gr




Fig. 1 Structure of the Ro/La ribonucleoprotein complex

termolecular spreading against the same or other autoantigens. It is still unknown if any of the autoantibodies have a pathogenic potential, or they are all parts of a secondary response to salivary glands already damaged by another process.

Nevertheless, anti-Ro and anti-La antibodies appear to participate in the local autoimmune response in the affected exocrine glands as: (1) autoantibodies to Ro and La are found in the saliva of patients [3, 4] and (2) B-cells infiltrating the salivary glands contain intracytoplasmic immunoglobulins with anti-Ro and anti-La activity [5–7]. In this case, ectopic lymphoid germinal centers that contain antigen presenting dendritic cells, T-cells, and B lymphocytes are found, providing a conducive microenvironment for the propagation of the autoimmune response [6]. Finally, (3) an increased mRNA production of La in acinar epithelial cells has been observed [8] and (4) translocation and membrane localization of the La protein has been observed in conjunctival epithelial cells of Sjögren's syndrome patients [9]. Recent studies have also shown that cultured epithelial cells from patients with Sjögren's syndrome constitutively secrete exosomes that contain the major autoantigens Ro and La [10]. This mechanism may represent a pathway whereby intracellular autoantigens are presented to the immune system.

On clinical ground, pSS is characterized by a variety of extraglandular manifestations involving epithelium (autoimmune epithelitis) and extra-epithelial tissues. Several autoantibodies may relate with particular disease subgroups or clinical manifestations.

Autoantibodies Serving as Disease Markers

Ro/SSA and La/SSB The most common autoantibodies in patients with SS are the antibodies directed against the Ro/La RNP complex. These antibodies are detected in serum and can be produced locally in the affected salivary glands [6]. Anti-La antibodies are accompanied by anti-Ro antibodies, whereas anti-Ro antibodies can be found either with anti-La antibodies or solely. Structurally, human Ro/La RNP is composed of one of the four small, uridine rich hY RNAs (*human cytoplasmic RNAs*) non-covalently associated with at least three proteins, the Ro52, La, and Ro60 autoantigens (Fig. 1) [11, 12]. Additional components of the complex have been recently identified as the proteins calreticulin [13] and nucleolin [14]. The localization of these complexes is mainly cytoplasmic. Their protein components, however, can be found in the nucleus as well. Nucleic Ro60, Ro52, and La autoantigens are not associated with hY RNA. After the assembly of the Ro/La RNP in the nucleus, the complex is rapidly and quantitatively transported to the cytoplasm [15, 16]. Under certain circumstances (e.g., stress, UV radiation, or viral infection), some of the protein components of the Ro/La RNP complex can be found on the cell surface.

Ro52 belongs to the tripartite motif (TRIM) or RING-B-box-coiled-coil (RBCC) protein family, thus, comprising an N-terminal RING, followed by a B-box and a coiled-coil region. The RING is a cysteine-rich Zn^{+2} -binding motif of the form C_3HC_4 [17], which binds two Zn^{+2} ions in a tetrahedral manner (Fig. 2) [18]. The RING is predominantly a protein–protein interaction motif, which also acts as a ubiquitin–protein isopeptide (E3) ligase in the ubiquitination pathway [19]. The B-box is the second Zn^{+2} -binding motif of Ro52 and has the form CHC_3H_2 [20]. Ro52 can also




Fig. 2 Modeled structures of the N-terminal domain (1–84aa) and the C-terminal region (282–475aa) of human Ro52 autoantigen. These models were based on the structures of BRCA1 ring domain, Ubiquitin ligase protein RING2 and RAG-1 zinc binding domain (N-domain of Ro52) and Ret-finger protein like 1 (C-domain of Ro52)

homodimerize through its leucine zipper domain [21]. Several different proteomic functions have been suggested for Ro52, including DNA binding, protein interactions, and Zn²⁺-binding. Overall, most probably, Ro52 functions as transcription modulator, due to its domain organization. In line with many other RING-containing proteins, Ro52 is involved in ubiquitination pathway [22]. Recent findings suggest that Ro52 autoantigen is a RING-dependent E3 ligase that is overexpressed in patients. In this regard, Ro52 may be directly involved in the reduced cellular proliferation and increased apoptotic cell death that is observed in Sjögren's syndrome and SLE [23].

The B-cell epitopes of Ro52 have been mapped in various studies with different methods. The major immunoreactivity of Ro52 kD autoantigen was localized, using recombinant Ro52 fusion proteins, in the middle coiled-coil region of Ro52 [24–26]. The 190–245aa region of the amino acid sequence was reactive with almost all anti-Ro52 positive sera and was independent of associated diseases [26]. An epitope spanning the 200–239aa of Ro52, which contains the complete leucine zipper motif, has been also identified in the same region [27]. Autoantibodies against this epitope were associated with neonatal lupus and congenital heart block. These autoantibodies have the potential to bind on the cell surface of cardiomyocytes in primary cultures and cause a dysregulation of the Ca²⁺-homeostasis, which is followed by apoptosis [28]. Anti-Ro52 antibodies are also found in primary biliary cirrhosis associated with sicca syndrome. The anti-Ro52 antibodies in this setting are directed against a smaller epitope than in primary Sjögren's Syndrome [29].

The Ro60 antigen is found in virtually all vertebrate cells and the nematode *Caenorhabditis elegans* [30]. Its function is related with the quality control or discard pathway for nascent transcripts synthesized by RNA polymerase III (e.g., 5 S rRNA precursors). Thus, Ro60 binds misfolded small RNAs (e.g., 5 S RNA) and lead them to degradation [30]. Recently, the structure of the *Xenopus laevis* Ro60, 78% identical to human Ro60, was solved and found to consist of two distinct domains (Fig. 3) [31]. One domain resembles the von Willebrand Factor A (vWFA) domain, which is found in extracellular matrix proteins and proteins that function in cell adhesion. The other domain consists of a series of alpha-helical repeats (HEAT repeats) that are arranged orbicularly around an inner hole of 10–15 Å (“doughnut”-like structure). This hole most probably holds the 3' ends of misfolded RNAs, while the YRNAs bind to conserved residues to the outside of the “doughnut”. Another conserved role for the Ro60 in facilitating cell survival after ultraviolet irradiation has recently emerged from studies in radiation-resistant eubacterium *Deinococcus radiodurans* [32] and mammalian cells lacking Ro60 [33]. Studies of mice lacking the Ro60 kD protein suggest also that the




Fig. 3 Structure of *Xenopus laevis* Ro60, complexed with RNAs

normal function of Ro may be important for the prevention of autoimmune disease [33]. In these studies, mice lacking Ro were found to develop autoantibodies and membranoproliferative glomerulonephritis.

Epitopes of Ro60 kD have been described by several authors using a variety of epitope mapping procedures [34, 35]. Initially, the major antigenic region of Ro60 kD identified within the central part of the molecule [36–38] (within 181–320aa, 139–326aa, and 155–295aa regions of the sequence, respectively). The fine localization of the antigenic determinants was revealed after the application of epitope mapping with synthetic peptides. Wahren et al. [35] identified a major epitope in synthetic peptide 216–245aa, Scofield and associates, identified numerous epitopes covering the entire length of Ro60 [39, 40] (presumptively, due to extended epitope spreading), and our group defined the antigenic regions of Ro60 kD in 169–190 and 211–232 parts of the antigen [41]. One of them, the 169–190 epitope, was found to share conformational and antigenic similarity with HLADR3 β -chain, an HLA class II allele, which was described to be highly associated with the anti-Ro60 response [42]. The same epitope was recently found to be the initial pre-disease target of autoantibodies in individuals, who developed SLE several years later [43]. This initial epitope has been reported to directly cross-react with a peptide from the latent viral protein Epstein–Barr virus nuclear antigen-1 (EBNA-1) [43, 44]. Recent studies suggest also that although the exact Ro epitopes were identified as small peptidic moieties, their recognition by autoantibodies is

conformation-dependent and is dramatically enhanced upon interaction with the molecular chaperone calreticulin [45].


The La antigen is a phosphoprotein that associates with a variety of small RNAs, including 5 S cellular RNA, tRNA, 7 S RNA, and hY RNAs, all transcribed by RNA polymerase III [46]. In molecular level, it binds a short polyuridylylate sequence (poly-U) that exists at the 3' end of almost all nascent pol III transcripts. Moreover, La binds viral RNAs [e.g. adenovirus VA (virus associated RNA), Epstein Barr EBER (EBV encoded RNA)], viral and human RNAs possessing IRES (internal ribosomal entry elements), and RNA component of telomerase complex [47]. Structurally, human La is a multidomain protein that contains the La motif in its N-terminal region, a typical RNA recognition motif (RRM) in its central part and an unusual RRM, encompassing residues 229–326. The latter is followed by a long, flexible polypeptide that contains a short basic motif (SBM), a regulatory phosphorylation site on Ser366, and a nuclear localization signal (NLS). Recently, the three-dimensional structure of the La-motif, the central RRM, and the carboxyl-terminal RNA recognition domain of the autoantigen were solved (Fig. 4) [48, 49]. The La motif folds into a winged-helix motif elaborated by the insertion of three helices. The central RRM consists of a four-strand β -sheet attached to two α -helices, while the C-terminal domain folds to generate a five-stranded, antiparallel β sheet surface that is terminated by a long α helix. It seems that both the La motif and the adjacent central RRM are required for high-affinity poly-U RNA binding and that the C-terminal RRM, in conjunction with the SBM downstream, contributes to La interactions with non-poly-U RNA targets such as viral RNAs and TOP (terminal oligopyrimidine) mRNAs [50]. The specific binding of La to precursor RNA molecules protects them from exonuclease digestion, and thereby, regulates their downstream processing. La also serves to retain precursor RNA molecules in the nucleus. Other cellular functions of La/SS-B autoantigen include an ATP-dependent helicase activity that melts RNA–DNA hybrids, unwinding ability of double-stranded

RNA, association with telomerase and influencing telomere homeostasis, an RNA chaperone activity performed by transient bipartite (5'- and 3'- end) binding of nascent transcripts synthesized by polymerase III (e.g., tRNA precursors), the induction of cap-independent translation (La binds IRES to elements and promotes the internal, cap-independent initiation of translation).

During the last decade, the target epitopes of anti-La/SS-B autoantibodies have been mapped [34]. Some of the La epitopes were found to reside in functional regions of the autoantigen, like the central RNA recognition motif (RRM) and the ATP binding site. However, the interaction of hYRNA with the RRM motif did not affect the autoantibody binding in the same region. In contrast, the interaction of the ATP binding site with ATP abolished the autoantibody binding at the same part of the protein. Highly antigenic peptides were identified in the sequences: $^{147}\text{HKAFKGS}^{154}$ (147–154aa) (located within central RRM motif), $^{291}\text{NGNLQLRNKEVT}^{302}$ (291–302aa), $^{301}\text{VTWEVLEGEVEKEA-LKKI}^{318}$ (301–318aa), and $^{349}\text{GSGKGVQFQGKTKF}^{364}$ (349–364aa) [51]. The most sensitive and specific epitope was 349–364aa, which showed a sensitivity and specificity of greater than 90%. Other epitopes have also been identified in other parts of the molecule using recombinant fragments of La/SS-B or synthetic peptides [2]. Their existence is believed to be correlated with extended intramolecular spreading of epitopes to the whole La/SS-B molecule.

Clinical significance of anti-Ro and anti-La antibodies Anti-Ro and anti-La antibodies are found in approximately 60–90 and 30–60% of patients with primary Sjögren's syndrome, respectively [52], depending on the method used for their detection. A variety of methods have been applied for the detection of anti-Ro and anti-La antibodies. Among them, RNA precipitation is considered as the gold standard method by various authors. However, this method cannot be used in everyday routine analysis, but it is useful as reference and confirmatory assay. More specifically,

Fig. 4 Structures of the N-terminal RRM (5-189aa) (complexed with polyU RNA), the central RRM (107-193aa) and the C-terminal region (229-326aa) of human La autoantigen



counter-immunoelectrophoresis (CIE) and immunodiffusion (ID) are commonly used for the detection of anti-Ro and anti-La antibodies. However, in a small subpopulation of patient sera, precipitin-negative anti-La/SS-B antibodies can be found. These antibodies are believed to possess restricted epitope recognition and can be detected without problem using an anti-La enzyme-linked immunosorbent assay (ELISA) assay. Immunoblotting (IB) can be used for the detection of anti-La antibodies, but it lacks sensitivity for the detection of anti-Ro antibodies.

The presence of these antibodies in patients with suspected primary Sjögren's syndrome strongly supports the diagnosis. In patients with pSS, anti-Ro and anti-La antibodies are associated with a higher prevalence of extraglandular features, especially vasculitis and higher intensity of the lymphocytic infiltrates in the affected salivary glands [52]. Anti-Ro and anti-La antibodies are present in only 5–15% of patients with secondary Sjögren's syndrome associated with rheumatoid arthritis and 38.5% of secondary-SS/SLE patients [53]. Pregnancy in women with anti-Ro and anti-La antibodies may be complicated by the development of neonatal lupus in the fetus or neonate with increased risk for congenital heart block, the most serious manifestation of this disorder [54]. It is presumed that in this rare syndrome, maternal anti-Ro and anti-La IgG autoantibodies pass through the placenta to the fetal circulation and cause tissue injury to the heart and skin. It is thought that that redistribution of Ro and La autoantigens to the surface of myocardial cells is required to become available for binding of autoantibodies. Such redistribution can be induced either by β -estradiol, viral infection, or apoptosis [55]. Recently, it was found that the presence of antiidiotypic antibodies to autoantibodies against La/SS-B may protect the fetus by blocking pathogenic maternal autoantibodies [56]. In this regard, sera from mothers that gave birth to a healthy child and without history of a child with NLS exhibit higher antiidiotypic antibody activity compared with mothers which gave birth to a child with NLS [56].

Autoantibodies Associated with Particular Disease Manifestations

Anti-centromere antibodies (ACA) Antibodies against centromere are found in patients with limited cutaneous sclerosis and a small percentage of patients with primary Sjögren's syndrome and idiopathic Raynaud's phenomenon [57] (Table 1). The SS patients with ACA are characterized by a lower incidence of parotid gland enlargement and anti-Ro anti-La antibodies [57]. Moreover, the ACA-positive patients were more likely to have Raynaud's phenomenon and sclerodactyly and less likely to have leukopenia, polyclonal

Table 1 Correlations of specific autoantibodies with disease manifestations

Disease manifestation	Related autoantibody
Raynaud's phenomenon and sclerodactyly	Anti-centromere
Distal renal tubular acidosis	Anti-carbonic anhydrase II
Glandular hypofunction and reduced sensitivity to muscarinic stimulation	Anti-muscarinic receptors
Liver pathology and primary biliary cirrhosis	Anti-mitochondrial
Increased risk of lymphoma and indicator of severe salivary gland damage	Rheumatoid factors
Frequent evolution to malignant lymphomas and severe internal organ involvement	Cryoglobulins

hypergammaglobulinemia, and rheumatoid factor [58]. The main target of anti-centromere antibodies was recently defined as the centromere proteins (CENP). In a subset representing 15% of SS patients, anticentromere antibodies recognize exclusively CENP-C [59]. Anti-CENP-H antibodies were also found in patients with SS. Patients with anti-CENP-H antibodies had a lower frequency of rheumatoid factor (RF) and anti-Ro/SS-A and/or anti-La/SS-B antibody [60].

Antibodies to carbonic anhydrase II Anti-carbonic anhydrase II antibody can be detected in a number of serum samples from patients with Sjögren's syndrome [61–63]. Carbonic anhydrase is an enzyme that catalyzes the reversible hydration of carbon dioxide to generate a proton and a bicarbonate ion, regulates the acid–base homeostasis in erythrocytes, the aqueous chamber of the eye, and the renal tubules [64]. Carbonic anhydrase II is the only soluble form of the enzyme and is found in the cytosol of both proximal and distal renal tubular cells [65]. When carbonic anhydrase II was used in immunization experiments, the immunized mice developed systemic exocrine gland inflammation similar to that observed in Sjögren syndrome [66].

Clinical significance of antibodies to carbonic anhydrase II Among patients with Sjögren syndrome, those with distal renal tubular acidosis had higher levels of anti-carbonic anhydrase II antibody than did those without renal tubular acidosis [67]. These results indicate that distal renal tubular acidosis in Sjögren syndrome may be caused, at least in some patients, by defective function of carbonic anhydrase II resulting from high plasma levels of carbonic anhydrase II autoantibodies.

Anti-muscarinic receptors It is known that acetylcholine (ACh) mediates glandular secretion, through a family of muscarinic receptor subtypes [68]. The muscarinic receptor family is encoded by five separate genes [69, 70], which

give five muscarinic gene products, designated M1R–M5R [71]. In the bladder and the colon, the muscarinic receptor population primarily comprises the M2R subtype (80% M2R and 20% M3R) [72], while in the parotid gland, the M3R represents the 93% of the muscarinic receptor population [73]. Studies with M3R- and M1R-knockout mice demonstrated that the M3R, but not the M1R, is essential for parasympathetic control of salivation [74]. In some patients with SS, autoantibodies directed against M3R acetylcholine receptors may block neuroglandular transmission, thereby, resulting in sicca symptoms [75–77]. In addition, antibodies raised against the second extracellular loop of the human muscarinic M3R receptor have been found to mimic functional autoantibodies in Sjögren's syndrome [78]. The most important evidence for the pathogenic role of anti-M3R antibodies was obtained by passive transfer experiments. In these experiments, transfer of SS IgG to mice have indicated that the recipient mice develop glandular hypofunction [77] and exhibit up-regulated M3R expression in bronchioles and marked hyperresponsiveness of bladder smooth muscle [79]. Furthermore, monovalent Fab fragment of IgG in patients with SS was found to inhibit cholinergic neurotransmission, indicating that the antimuscarinic antibody activity does not require receptor cross-linking [80]. However, this antimuscarinic antibody activity was neutralized in vitro by antiidiotypic antibodies in both pooled intravenous immunoglobulin (IVIg) and IgG from healthy individuals [80], suggesting the possibility that naturally occurring antiidiotypic antibodies may prevent the emergence of antimuscarinic autoantibodies. Data from immunofluorescence experiments using rat lacrimal glands revealed recognition of M3R by SS IgG. The immunofluorescent signal, in these experiments, could be quenched by preincubation of the SS IgG with a synthetic peptide corresponding to the second extracellular loop of M3R [81]. Moreover, the same M3R peptide could be used to detect anti-M3R IgG antibodies in SS sera [82] and IgA antibodies in SS saliva [83] by ELISA. Western blotting has also been reported as a suitable method for the detection of anti-M3R antibodies in SS sera, using crude lacrimal membrane fractions as a source of M3R [76]. However, in a more recent work of Dawson LJ and coworkers, it was found that there is no detectable anti-M3R activity in SS sera by Western blotting when membranes, obtained from Chinese hamster ovary (CHO) cells that had been stably transfected with functional human M3R, were used as antigen source [84]. In contrast, another study using M3R-transfected CHO cells for a flow cytometric assay, indicated that anti-M3R may be present in SS sera [85]. Therefore, further studies are needed to elucidate the discrepancies in these findings.

Recent experimental data strongly indicate that the second extracellular loop of M3R is the target antigen in SS, but this

has not been demonstrated conclusively. An epitope was recently identified in the 213–228aa region of this domain, and an ELISA system, which enables the measurement of anti-M3AChR213-228 antibody levels on a large scale has been developed [86]. Anti-M3AChR213-228 antibody positivity was observed in 90% of the pSS patients, 29% of sSS patients, 35% of RA patients, 32% of SLE patients, and none of the healthy controls [87]. However, all the antigenic regions of M3R are not currently known in detail, and it is apparently necessary for the future research on antimuscarinic antibodies to focus on identifying all epitopes recognized by SS sera. A starting point for determining additional epitopes may be derived from data demonstrating that the cleavage of M3R by granzyme B (during cytotoxic lymphocyte granule-induced cell death) results in the generation of novel fragments with pathogenetic potential [88].

Clinical significance of anti-muscarinic receptors Sjögren's syndrome has been described as “an autoimmune epithelitis” of the exocrine glands, which particularly involves the salivary and lacrimal glands. The secretory tissues in the affected glands are progressively destroyed and replaced by a lymphoreticular cell infiltrate, losing a significant amount of their function. It has been recently proposed that the pathology underlying the glandular hypofunction contributes inhibitory autoantibodies directed against muscarinic receptors. These antibodies may be found in both primary and secondary SS [89–91], and therefore, they would serve to unite the pathologies underlying the glandular hypofunction of both primary and secondary SS. In animal models, autoantibodies directed against salivary gland muscarinic receptors were found to decrease glandular secretion [77]. In SS patients, isolated salivary acinar cells remain functional in vitro [92, 93], but with a reduced sensitivity to threshold levels of muscarinic stimulation [93], suggesting that the lack of glandular function in many patients with SS is the result of a perturbation of acinar function [94, 95]. In addition, perturbation of muscarinic receptor function by the presence of antimuscarinic antibodies would account, in large part, for some of the reported extraglandular features of SS, such as bladder irritability [90, 96, 97], impairment of esophageal motor function [98], and microvascular responses to cholinergic stimulation [99], Adie pupil [100], and variable heart rate [101]. In one study, the antibody levels against the 213–228aa peptide of M3R correlated positively with the number of extraglandular organ manifestations [87].

Antimitochondrial antibodies Antimitochondrial antibodies (AMA) is a diagnostic marker for primary biliary cirrhosis (PBC), a chronic cholestatic liver disease predominantly affecting middle aged women [102]. In pSS, 7% of patients shows evidence of liver disease either subclinical (2%) or

asymptomatic (5%) with elevated liver enzymes. Moreover, 6.6% of SS patients possess antimitochondrial antibodies (AMA). AMA is conventionally detected by immunofluorescence, and their major molecular targets have been identified to be dihydrolipoamide acyltransferases (E2 subunits) of the 2-keto acid dehydrogenase enzyme complex (mainly the E2 component of the pyruvate dehydrogenase complex) [103]. Ninety-two percent of the SS patients with AMA exhibit liver involvement with histological features of chronic cholangitis similar to stage I PBC [104]. Therefore, AMA appeared to be a sensitive indicator of underlying liver pathology in pSS patients. In a subsequent study, it was also concluded that although AMA is a rare finding in patients with SS, their presence predispose them to develop PBC upon a 5-year follow-up [105]. Thus, it seems that patients with SS and AMA are usually in an early asymptomatic stage of PBC.

Rheumatoid factors and cryoglobulins The rheumatoid factors were first identified by Waaler in 1940 [106], and these autoantibodies were named rheumatoid factor by Pike in 1949 [107] due to their association with rheumatoid arthritis (RA), before the understanding that they were antibodies. It is now known that these autoantibodies bind to the Fc portion of IgG in the $\gamma 2$ – $\gamma 3$ cleft, but yet, many questions remain unanswered [108]. It has long been recognized that the RF response is transiently associated with many infectious diseases. In this case, the RF response may actually be beneficial as RF helps in the clearance of immune complexes by contributing to the formation of larger sized complexes, and therefore, facilitating their removal [109, 110]. In the rheumatic diseases, the existence of RF is associated with RA, where ~70% of patients are positive for RF [111], and pSS, where ~40–50% are positive for RF [112]. Approximately 20% of patients with Sjögren's syndrome have cryoglobulins in their sera [113]. Cryoglobulinemia is defined as the presence of circulating immunoglobulins that precipitate at temperatures below 37°C and redissolve on rewarming [114, 115]. According to cryoprecipitate composition, cryoglobulinemia is classified into three serological subsets: monoclonal cryoimmunoglobulinemia (type I) composed of single monoclonal immunoglobulin, mixed cryoglobulinemia containing a mixture of polyclonal IgG, and monoclonal (type II) or polyclonal (type III) IgM rheumatoid factor [114]. Type I cryoglobulinemia is frequently associated with well-known hematological disorders, while types II and III mixed cryoglobulinemia can be further classified as essential or secondary in the absence/presence of other well defined infectious, immunological, or neoplastic diseases [116].

Clinical significance of rheumatoid factors and cryoglobulins RFs potentially play an important role in the pathogenesis of pSS, as they have been shown to be an indicator of the

severity of salivary gland damage [117]. In addition, there is an increased risk of lymphoma in SS [118] with an incidence of 12.2 per 1,000 person years [119]. The expansion of monoclonal RF has been demonstrated in a high percentage of the cases [120, 121]. In a study of a large cohort of patients with primary SS, individuals who developed lymphoma had mixed cryoglobulinemia both at initial diagnosis of SS and at follow-up, thus indicating that the mixed cryoglobulinemia was a detrimental prognostic event [119]. It has been proposed that RFs contribute in lymphomagenesis in pSS [122]. According to this theory, the first event is the chronic stimulation at the site of the disease of polyclonal B cells secreting rheumatoid factor (RF). Then, these RF-B cells may become monoclonal and disseminate in other organs. The monoclonal secreted RF complexed with polyclonal IgG may also cryoprecipitate. Afterwards, a chromosomal abnormality may confer to these cells a low-grade B cell lymphoma compartment. At last, an event (e.g., a mutation of p53) might transform this low grade B cell lymphoma into a high grade, large B cell lymphoma. These lymphoma B cells have been recently found to display RF activity, supporting the proposed hypothesis [121]. The presence of cryoglobulinemia seems to identify a particular clinical subset of Sjögren's syndrome, characterized by a poor prognosis due to more severe internal organ involvement and frequent evolution to malignant lymphomas [113, 123].

Other Autoantibodies

Anti-alpha-fodrin and anti-beta-fodrin Although no pathogenic role has yet been found for antibodies directed against alpha-fodrin and beta-fodrin, these antibodies are present in many SS patients. Alpha-fodrin is a 240-kDa protein forming a heterodimer with either beta-fodrin, a 235-kDa molecule that is homologous to alpha-fodrin, or with beta-spectrins [124]. These heterodimers can self-associate into tetramers [125], which are anchored to the plasma membrane and bind to actin, calmodulin, and microtubules [125]. Therefore, alpha-fodrin is a fundamental constituent of the membrane skeleton. In addition, alpha-fodrin has been shown to associate with membrane ion channels and pumps and appears to be involved in control of secretion from glands [126, 127]. Antibodies against alpha-fodrin have been shown to block nerve conduction in glutamate and other synapses present in salivary glands [128, 129]. From this point of view, antibodies against alpha-fodrin may interfere with the nerve impulses regulating secretions from the salivary and lacrimal glands providing a potential mechanism for the dysfunction of these glands that is observed in SS. In early reports, IgG antibodies against

alpha-fodrin were found in 95% (41/43) of the patients with primary Sjögren's syndrome (classified according to the Japanese criteria for Sjögren's syndrome) and 63% (5/8) with secondary Sjögren's syndrome, but none of patients with SLE, RA, or healthy individuals [130]. In subsequent studies, IgG antibodies against alpha-fodrin were detected in approximately 67 [131], 55 [132], 23 [133], or 2% [134] of SS patients, whereas IgA antibodies against alpha-fodrin were found in 64% of the SS patients [132]. Moreover, antibodies against alpha-fodrin can be found in 40% of patients with RA [135], 20% of patients with multiple sclerosis (MS) [135], and 47% of those with SLE without sicca symptoms [133]. Given that antibodies against alpha-fodrin are not characterized by the initially reported prevalence and disease specificity [130], their diagnostic value is questionable [136]. In this regard, Zandbelt et al. and Turkçapar et al. reported that measurement of anti- α -fodrin autoantibodies does not add much to the diagnosis of Sjögren's syndrome, as anti-Ro and anti-La autoantibodies are more sensitive than anti-alpha-fodrin for the diagnosis of SS and anti-La autoantibodies are also more specific [137, 138]. Beta-fodrin has also been shown to be an autoantibody target, associated with Sjögren's syndrome, and have been characterized in 51% of primary SS and 84% of secondary SS [139]. These antibodies were directed against the N-terminal domain of beta-fodrin, the only domain that is not homologous to alpha-fodrin. Insights for the potential role of alpha-fodrin in the pathogenesis of SS were gained from a mouse model of Sjögren's syndrome. In this model, NFS/*sld* mice were thymectomized on day 3 after birth, and thus, the CD4+CD25+ regulatory T cells were removed [130]. Later on, these mice developed lymphocytic infiltrates in the salivary glands as a histological sign of Sjögren's syndrome [130]. Analysis of the sera of these mice in immunoblots with organ extracts of the same mice revealed a 120-kDa band, which was subsequently sequenced and identified as a cleavage product of alpha-fodrin. The autoantibodies were recognized the cleavage product, but not the complete alpha-fodrin. This 120-kDa cleavage product of alpha-fodrin has been reported to be generated during apoptosis, by caspase 3 [140]. In line with this observation, treatment of the mice with inhibitors of caspases prevented induction of Sjögren's syndrome [141]. In SS patients, cleaved alpha-fodrin was detected in labial salivary glands and found to co-localize with PARP and caspase-3 along with DNA fragmentation [142]. Taken together, cleaved alpha-fodrin may be better antigenic substrate than intact alpha-fodrin for the detection of SS specific autoantibodies, but further studies are required to ascertain the specific association of cleaved alpha-fodrin with Sjögren's syndrome.

Clinical significance of anti-alpha-fodrin and anti-beta-fodrin Anti-fodrin antibodies are found not only in SS, but

also in other autoimmune diseases such as RA and SLE. Therefore, they cannot serve as sensitive and specific markers for SS. On the other hand, follow-up of SS patients treated with antimalarials or low-dose glucocorticosteroids revealed that the concentration of antibodies against alpha-fodrin may fall within 3 months [135]. In addition, the titer of antibodies against alpha-fodrin is correlated to the degree of lymphocytic infiltration in the salivary glands [135]. Although, antibodies against alpha-fodrin appear to reflect the disease activity of SS, additional study of the clinical use of testing for anti-alpha-fodrin antibodies is needed to assess their role in the monitoring of the disease activity in Sjögren's syndrome.

Islet cell autoantigen Islet cell autoantigen 69 (ICA69) is a 69-kD protein that is present in salivary and lacrimal glands and pancreatic beta cells and tissue of the nervous system. In one study, elevated levels of autoantibodies to this protein were frequently found in the serum of patients with primary SS (eight of nine patients), but not in patients with SLE (zero of six) or in healthy controls (0 of 12) [143]. In a murine model of SS (the nonobese diabetic or NOD mouse), in which spontaneous lymphocytic infiltration of the lacrimal and salivary glands occurs, animals that did not express the ICA69 protein had a markedly slower progression of glandular lymphocytic infiltration than wild-type or heterozygous ICA69 knockouts [143]. However, larger studies are required to confirm the differential presence in SS vs SLE, or other rheumatic disorders, so that testing for these antibodies may find a role in clinical practice.

Poly(ADP)ribose polymerase Poly(ADP)ribose polymerase (PARP) is a chromatin-bound, DNA-dependent enzyme that catalyzes the ADP-ribosylation of nuclear acceptor proteins by using NAD⁺ as a substrate [144]. Proteins that are covalently modified by poly(ADP)ribose polymerase include DNA topoisomerases I, II, DNA polymerases α and β , RNA polymerase II, histones H1 and H2B, and lamins [145]. PARP displays a three-domain structure, which can be further broken down into modules A-F [146]. The N-terminal 42 kDa DNA-binding domain also comprises the nuclear localization signal of the protein and is adjacent to a central 16 kDa automodification domain. The 55 kDa catalytic domain, which includes the active site, is located at the C-terminus. The N-terminal region of PARP binds to single- or double-strand breaks with high affinity via two zinc fingers. Non-B DNA structures, such as DNA hairpins, cruciforms, and stably unpaired regions are all effective activators of PARP leading to poly(ADP)-ribosylation of substrates like histone H1 [144]. Sera with autoantibodies to PARP recognize the NAD-binding domain of the enzyme, as demonstrated by either immunoblotting or immunoprecip-

itation of partially proteolyzed ADP ribose polymerase [147]. These autoantibodies are identified in SS and related rheumatic diseases and found to inhibit the catalytic activity of PARP, as measured by the transfer of ADP-ribose from ^{32}P -NAD to either histones or to PARP itself [147, 148]. Negri et al. reported that only a few patients with SS actually possess anti-PARP antibodies [149]. Muller et al. identified a 44-mer peptide epitope in the second zinc finger of the DNA-binding domain of PARP. This epitope was recognized by 42% of pSS and 56% of sSS sera [150]. Recently, it was reported that cleaved PARP together with activated caspase 3 is elevated in ductal and acinar cells of SS salivary glands, but not in normal salivary glands [151].

NuMA In some cases “anti-mitotic spindle” autoantibodies, staining mitotic poles, and spindles of Hep-2 cells in indirect immunofluorescence (IIF), are identified during laboratory routine. These autoantibodies most commonly target type-1 nuclear mitotic apparatus (NuMA-1) [152]. In one study, autoantibodies against NuMA-1 were identified in patients, who had clinical and minor salivary gland biopsy findings compatible with Sjögren’s syndrome at 53% [153]. However, in a more recent study [154], anti-NuMA antibodies were not found to prevail in any defined rheumatic disease. None of the patients in this study fulfilled the criteria for Sjögren’s syndrome [154].

Golgins Anti-Golgi complex autoantibodies were first identified in the serum of a Sjögren’s syndrome patient with lymphoma [155]. These autoantibodies have been identified primarily in patients with Sjögren’s syndrome and systemic lupus erythematosus, although they are not restricted to these diseases [156]. The Golgi complex is an organelle with a prominent function in the processing, transporting, and sorting of intracellular proteins subsequent to their synthesis in the rough endoplasmic reticulum. Structurally, the Golgi complex is localized in the perinuclear region of most mammalian cells and is characterized by stacks of membrane-bound cisternae [157]. Autoantibodies against this complex commonly target autoantigens like giantin [156] and golgin-97 [158]. Antibodies to golgin-97 have been identified in SS patient sera [158].

90-kDa nucleolar organizer region protein Autoantibodies to nucleolar transcription factor NOR 90/hUBF (anti-NOR 90) were detected in about 10% of sera. The majority of these sera (78%) is reported to belong to patients with SS [159]. More recent data suggest that anti-NOR90 is a rare autoantibody specificity, associated with Reynaud phenomenon [160, 161].

Lipocalin Navone R et al. screened a random peptide library with pooled IgG immunoglobulins derived from patients

with primary SS. Among the identified peptides, one was recognized by the majority of patients’ sera, but not by sera of normal donors and of patients with other autoimmune diseases. This peptide (SS-peptide) showed homology with Epstein Barr Virus (EBV) derived early antigen protein D, with tear lipocalin and with alpha-fodrin [162]. Lipocalin is a protein highly expressed in tears and saliva and account for 15–33% of the amount of proteins in tears. Its function is to lubricate the eyelids, to form a smooth and even layer over the corneal surface, and to create an antimicrobial system for the ocular surface [163]. It may also act as a scavenger of lipophilic, potentially harmful substances protecting the epithelium [164]. Lipocalin was specifically recognized by anti-SS-peptide antibodies, affinity purified from patients’ sera. The same antibodies also recognized the viral early antigen protein D and alpha-fodrin, providing a potential link between viral infection, apoptosis, and disruption of lipocalin’s protective function in tears and saliva [162].

References

1. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Tala N, Weisman MH (2002) Classification criteria for Sjogren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. *Ann Rheum Dis* 61:554–558
2. Routsias JG, Vlachoyiannopoulos PG, Tzioufas AG (2006) Autoantibodies to intracellular autoantigens and their B-cell epitopes: molecular probes to study the autoimmune response. *Crit Rev Clin Lab Sci* 43:203–248
3. Iwasaki K, Okawa-Takatsuji M, Aotsuka S, Ono T (2003) Detection of anti-SS-A/Ro and anti-SS-B/La antibodies of IgA and IgG isotypes in saliva and sera of patients with Sjogren’s syndrome. *Nihon Rinsho Meneki Gakkai Kaishi* 26:346–354
4. Hammi AR, Al-Hashimi IH, Nunn ME, Zipp M (2005) Assessment of SS-A and SS-B in parotid saliva of patients with Sjogren’s syndrome. *J Oral Pathol Med* 34:198–203
5. Halse A, Harley JB, Kroneld U, Jonsson R (1999) Ro/SS-A reative B lymphocytes in salivary glands and peripheral blood of patients with Sjogren’s syndrome. *Clin Exp Immunol* 115:203–207
6. Salomonsson S, Jonsson MV, Skarstein K, Brokstad KA, Hjelmstrom P, Wahren-Herlenius M, Jonsson R (2003) Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjogren’s syndrome. *Arthritis Rheum* 48:3187–3201
7. Salomonsson S, Larsson P, Tengner P, Mellquist E, Hjelmstrom P, Wahren-Herlenius M (2002) Expression of the B cell-attracting chemokine CXCL13 in the target organ and autoantibody production in ectopic lymphoid tissue in the chronic inflammatory disease Sjogren’s syndrome. *Scand J Immunol* 55:336–342
8. Tzioufas AG, Hantoumi I, Polihronis M, Xanthou G, Moutsopoulos HM (1999) Autoantibodies to La/SSB in patients with primary Sjogren’s syndrome (pSS) are associated with upregulation of La/SSB mRNA in minor salivary gland biopsies (MSGs). *J Autoimmun* 13:429–434

9. Yannopoulos DI, Roncin S, Lamour A, Pennec YL, Moutsopoulos HM, Youinou P (1992) Conjunctival epithelial cells from patients with Sjogren's syndrome inappropriately express major histocompatibility complex molecules, La(SSB) antigen, and heat-shock proteins. *J Clin Immunol* 12:259–265
10. Kapsogeorgou EK, Abu-Helu RF, Moutsopoulos HM, Manoussakis MN (2005) Salivary gland epithelial cell exosomes: a source of autoantigenic ribonucleoproteins. *Arthritis Rheum* 52:1517–1521
11. Ben-Chetrit E, Chan EK, Sullivan KF, Tan EM (1988) A 52-kD protein is a novel component of the SS-A/Ro antigenic particle. *J Exp Med* 167:1560–1571
12. Slobbe RL, Pluk W, van Venrooij WJ, Pruijn GJ (1992) Ro ribonucleoprotein assembly in vitro. Identification of RNA-protein and protein-protein interactions. *J Mol Biol* 227:361–366
13. Cheng ST, Nguyen TQ, Yang YS, Capra JD, Sontheimer RD (1996) Calreticulin binds hYRNA and the 52-kDa polypeptide component of the Ro/SS-A ribonucleoprotein autoantigen. *J Immunol* 156:4484–4491
14. Fouraux MA, Bouvet P, Verkaar S, van Venrooij WJ, Pruijn GJ (2002) Nucleolin associates with a subset of the human Ro ribonucleoprotein complexes. *J Mol Biol* 320:475–488
15. Peek R, Pruijn GJ, van der Kemp AJ, van Venrooij WJ (1993) Subcellular distribution of Ro ribonucleoprotein complexes and their constituents. *J Cell Sci* 106:929–935
16. Simons FH, Pruijn GJ, van Venrooij WJ (1994) Analysis of the intracellular localization and assembly of Ro ribonucleoprotein particles by microinjection into *Xenopus laevis* oocytes. *J Cell Biol* 125:981–988
17. Krishna SS, Majumdar I, Grishin NV (2003) Structural classification of zinc fingers: survey and summary. *Nucleic Acids Res* 31:532–550
18. Barlow PN, Luisi B, Milner A, Elliott M, Everett R (1994) Structure of the C3HC4 domain by 1H-nuclear magnetic resonance spectroscopy. A new structural class of zinc-finger. *J Mol Biol* 237:201–211
19. Hershko A, Ciechanover A (1998) The ubiquitin system. *Annu Rev Biochem* 67:425–479
20. Borden KL, Martin SR, O'Reilly NJ, Lally JM, Reddy BA, Etkin LD, Reemont PS (1993) Characterisation of a novel cysteine/histidine-rich metal binding domain from *Xenopus* nuclear factor XNF7. *FEBS Lett* 335:255–260
21. Wang D, Buyon JP, Yang Z, Di Donato F, Miranda-Carus ME, Chan EK (2001) Leucine zipper domain of 52 kDa SS-A/Ro promotes protein dimer formation and inhibits in vitro transcription activity. *Biochim Biophys Acta* 1568:155–161
22. Frank MB (1999) Characterization of DNA binding properties and sequence specificity of the human 52 kDa Ro/SS-A (Ro52) zinc finger protein. *Biochem Biophys Res Commun* 259:665–670
23. Espinosa A, Zhou W, Ek M, Hedlund M, Brauner S, Popovic K, Horvath L, Wallerskog T, Oukka M, Nyberg F, Kuchroo VK, Wahren-Herlenius M (2006) The Sjogren's syndrome-associated autoantigen Ro52 is an E3 ligase that regulates proliferation and cell death. *J Immunol* 176:6277–6285
24. Blange I, Ringertz NR, Pettersson I (1994) Identification of antigenic regions of the human 52kD Ro/SS-A protein recognized by patient sera. *J Autoimmun* 7:263–274
25. Kato T, Sasakawa H, Suzuki S, Shirako M, Tashiro F, Nishioka K, Yamamoto K (1995) Autoepitopes of the 52-kd SS-A/Ro molecule. *Arthritis Rheum* 38:990–998
26. Dorner T, Feist E, Wagenmann A, Kato T, Yamamoto K, Nishioka K, Burmester GR, Hiepe F (1996) Anti-52 kDa Ro (SSA) autoantibodies in different autoimmune diseases preferentially recognize epitopes on the central region of the antigen. *J Rheumatol* 23:462–468
27. Salomonsson S, Dorner T, Theander E, Bremme K, Larsson P, Wahren-Herlenius M (2002) A serologic marker for fetal risk of congenital heart block. *Arthritis Rheum* 46:1233–1241
28. Salomonsson S, Sonesson SE, Ottosson L, Muhallab S, Olsson T, Sunnerhagen M, Kuchroo VK, Thoren P, Herlenius E, Wahren-Herlenius M (2005) Ro/SSA autoantibodies directly bind cardiomyocytes, disturb calcium homeostasis, and mediate congenital heart block. *J Exp Med* 201:11–17
29. Dorner T, Feist E, Held C, Conrad K, Burmester GR, Hiepe F (1996) Differential recognition of the 52-kd Ro(SS-A) antigen by sera from patients with primary biliary cirrhosis and primary Sjogren's syndrome. *Hepatology* 24:1404–1407
30. Chen X, Wolin SL (2004) The Ro 60 kDa autoantigen: insights into cellular function and role in autoimmunity. *J Mol Med* 82:232–239
31. Stein AJ, Fuchs G, Fu C, Wolin SL, Reinisch KM (2005) Structural insights into RNA quality control: the Ro autoantigen binds misfolded RNAs via its central cavity. *Cell* 121:529–539
32. Chen X, Quinn AM, Wolin SL (2000) Ro ribonucleoproteins contribute to the resistance of *Deinococcus radiodurans* to ultraviolet irradiation. *Genes Dev* 14:777–782
33. Xue D, Shi H, Smith JD, Chen X, Noe DA, Cedervall T, Yang DD, Eynon E, Brash DE, Kashgarian M, Flavell RA, Wolin SL (2003) A lupus-like syndrome develops in mice lacking the Ro 60-kDa protein, a major lupus autoantigen. *Proc Natl Acad Sci U S A* 100:7503–7508
34. Moutsopoulos NM, Routsias JG, Vlachoyiannopoulos PG, Tzioufas AG, Moutsopoulos HM (2000) B-cell epitopes of intracellular autoantigens: myth and reality. *Mol Med* 6:141–151
35. Wahren-Herlenius M, Muller S, Isenberg D (1999) Analysis of B-cell epitopes of the Ro/SS-A autoantigen. *Immunol Today* 20:234–240
36. McCauliffe DP, Yin H, Wang LX, Lucas L (1994) Autoimmune sera react with multiple epitopes on recombinant 52 and 60 kDa Ro(SSA) proteins. *J Rheumatol* 21:1073–1080
37. Saitta MR, Amett FC, Keene JD (1994) 60-kDa Ro protein autoepitopes identified using recombinant polypeptides. *J Immunol* 152:4192–4202
38. Wahren M, Ruden U, Andersson B, Ringertz NR, Pettersson I (1992) Identification of antigenic regions of the human Ro 60 kDa protein using recombinant antigen and synthetic peptides. *J Autoimmun* 5:319–332
39. Scofield RH, Dickey WD, Jackson KW, James JA, Harley JB (1991) A common autoepitope near the carboxyl terminus of the 60-kD Ro ribonucleoprotein: sequence similarity with a viral protein. *J Clin Immunol* 11:378–388
40. Scofield RH, Harley JB (1991) Autoantigenicity of Ro/SSA antigen is related to a nucleocapsid protein of vesicular stomatitis virus. *Proc Natl Acad Sci USA* 88:3343–3347
41. Routsias JG, Tzioufas AG, Sakarellos-Daitsiotis M, Sakarellos C, Moutsopoulos HM (1996) Epitope mapping of the Ro/SSA60KD autoantigen reveals disease-specific antibody-binding profiles. *Eur J Clin Invest* 26:514–521
42. Routsias JG, Sakarellos-Daitsiotis M, Tsikaris V, Sakarellos C, Moutsopoulos HM, Tzioufas AG (1998) Structural, molecular and immunological properties of linear B-cell epitopes of Ro60KD autoantigen. *Scand J Immunol* 47:280–287
43. McClain MT, Heinlen LD, Dennis GJ, Roebuck J, Harley JB, James JA (2005) Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. *Nat Med* 11:85–89
44. Poole BD, Scofield RH, Harley JB, James JA (2006) Epstein-Barr virus and molecular mimicry in systemic lupus erythematosus. *Autoimmunity* 39:63–70
45. Staikou EV, Routsias JG, Makri AA, Terzoglou A, Sakarellos-Daitsiotis M, Sakarellos C, Panayotou G, Moutsopoulos HM, Tzioufas AG (2003) Calreticulin binds preferentially with B cell

- linear epitopes of Ro60 kD autoantigen, enhancing recognition by anti-Ro60 kD autoantibodies. *Clin Exp Immunol* 134:143–150
46. Wolin SL, Cedervall T (2002) The La protein. *Annu Rev Biochem* 71:375–403
 47. Routsias JG, Tzioufas AG, Moutsopoulos HM (2004) The clinical value of intracellular autoantigens B-cell epitopes in systemic rheumatic diseases. *Clin Chim Acta* 340:1–25
 48. Jacks A, Babon J, Kelly G, Manolaridis I, Cary PD, Curry S, Conte MR (2003) Structure of the C-terminal domain of human La protein reveals a novel RNA recognition motif coupled to a helical nuclear retention element. *Structure* 11:833–843
 49. Alfano C, Sanfelice D, Bbon J, Kelly G, Jacks A, Curry S, Conte MR (2004) Structural analysis of cooperative RNA binding by the La motif and central RRM domain of human La protein. *Nat Struct Mol Biol* 11:323–329
 50. Maraia RJ, Intine RV (2001) Recognition of nascent RNA by the human La antigen: conserved and divergent features of structure and function. *Mol Cell Biol* 21:367–379
 51. Tzioufas AG, Yiannaki E, Sakarellos-Daitsiotis M, Routsias JG, Sakarellos C, Moutsopoulos HM (1997) Fine specificity of autoantibodies to La/SSB: epitope mapping, and characterization. *Clin Exp Immunol* 108:191–198
 52. Harley JB, Alexander EL, Bias WB, Fox OF, Provost TT, Reichlin M, Yamagata H, Arnett FC (1986) Anti-Ro (SS-A) and anti-La (SS-B) in patients with Sjogren's syndrome. *Arthritis Rheum* 29:196–206
 53. Manoussakis MN, Georgopoulou C, Zintzaras E, Spyropoulou M, Stavropoulou A, Skopouli FN, Moutsopoulos HM (2004) Sjogren's syndrome associated with systemic lupus erythematosus: clinical and laboratory profiles and comparison with primary Sjogren's syndrome. *Arthritis Rheum* 50:882–891
 54. Buyon JP (1996) Neonatal lupus. *Curr Opin Rheumatol* 8:485–490
 55. Buyon JP, Clancy RM (2005) Neonatal lupus: basic research and clinical perspectives. *Rheum Dis Clin North Am* 31:299–313:vii
 56. Stea EA, Routsias JG, Clancy RM, Buyon JP, Moutsopoulos HM, Tzioufas AG (2006) Anti-La/SSB antiidiotypic antibodies in maternal serum: a marker of low risk for neonatal lupus in an offspring. *Arthritis Rheum* 54:2228–2234
 57. Vlachoyiannopoulos PG, Drosos AA, Wiik A, Moutsopoulos HM (1993) Patients with anticentromere antibodies, clinical features, diagnoses and evolution. *Br J Rheumatol* 32:297–301
 58. Caramaschi P, Biasi D, Carletto A, Manzo T, Randon M, Zeminian S, Bambara LM (1997) Sjogren's syndrome with anticentromere antibodies. *Rev Rhum Engl Ed* 64:785–788
 59. Pillemer SR, Casciola-Rosen L, Baum BJ, Rosen A, Gelber AC (2004) Centromere protein C is a target of autoantibodies in Sjogren's syndrome and is uniformly associated with antibodies to Ro and La. *J Rheumatol* 31:1121–1125
 60. Hsu TC, Chang CH, Lin MC, Liu ST, Yen TJ, Tsay GJ (2006) Anti-CENP-H antibodies in patients with Sjogren's syndrome. *Rheumatol Int* 26:298–303
 61. Kino-Ohsaki J, Nishimori I, Morita M, Okazaki K, Yamamoto Y, Onishi S, Hollingsworth MA (1996) Serum antibodies to carbonic anhydrase I and II in patients with idiopathic chronic pancreatitis and Sjogren's syndrome. *Gastroenterology* 110:1579–1586
 62. Itoh Y, Reichlin M (1992) Antibodies to carbonic anhydrase in systemic lupus erythematosus and other rheumatic diseases. *Arthritis Rheum* 35:73–82
 63. Inagaki Y, Jinno-Yoshida Y, Hamasaki Y, Ueki H (1991) A novel autoantibody reactive with carbonic anhydrase in sera from patients with systemic lupus erythematosus and Sjogren's syndrome. *J Dermatol Sci* 2:147–154
 64. Maren TH (1967) Carbonic anhydrase: chemistry, physiology, and inhibition. *Physiol Rev* 47:595–781
 65. Lonnerholm G, Ridderstrale Y (1980) Intracellular distribution of carbonic anhydrase in the rat kidney. *Kidney Int* 17:162–174
 66. Nishimori I, Bratanova T, Toshkov I, Caffrey T, Mogaki M, Shibata Y, Hollingsworth MA (1995) Induction of experimental autoimmune sialoadenitis by immunization of PL/J mice with carbonic anhydrase II. *J Immunol* 154:4865–4873
 67. Takemoto F, Hoshino J, Sawa N, Tamura Y, Tagami T, Yokota M, Katori H, Yokoyama K, Ubara Y, Hara S, Takaichi K, Yamada A, Uchida S (2005) Autoantibodies against carbonic anhydrase II are increased in renal tubular acidosis associated with Sjogren syndrome. *Am J Med* 118:181–184
 68. Birdsall NJ, Hulme EC, Stockton J, Burgen AS, Berrie CP, Hammer R, Wong EH, Zigmond MJ (1983) Muscarinic receptor subclasses: evidence from binding studies. *Adv Biochem Psychopharmacol* 37:323–329
 69. Bonner TI, Buckley NJ, Young AC, Brann MR (1987) Identification of a family of muscarinic acetylcholine receptor genes. *Science* 237:527–532
 70. Peralta EG, Ashkenazi A, Winslow JW, Smith DH, Ramachandran J, Capon DJ (1987) Distinct primary structures, ligand-binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors. *EMBO J* 6:3923–3929
 71. Caulfield MP, Birdsall NJ (1998) International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. *Pharmacol Rev* 50:279–290
 72. Ehlert FJ, Ostrom RS, Sawyer GW (1997) Subtypes of the muscarinic receptor in smooth muscle. *Life Sci* 61:1729–1740
 73. Dai YS, Ambudkar IS, Horn VJ, Yeh CK, Kousvelari EE, Wall SJ, Li M, Yasuda RP, Wolfe BB, Baum BJ (1991) Evidence that M3 muscarinic receptors in rat parotid gland couple to two second messenger systems. *Am J Physiol* 261:C1063–C1073
 74. Nakamura T, Matsui M, Uchida K, Futatsugi A, Kusakawa S, Matsumoto N, Nakamura K, Manabe T, Taketo MM, Mikoshiba K (2004) M(3) muscarinic acetylcholine receptor plays a critical role in parasympathetic control of salivation in mice. *J Physiol* 558:561–575
 75. Li J, Ha YM, Ku NY, Choi SY, Lee SJ, Oh SB, Kim JS, Lee JH, Lee EB, Song YW, Park K (2004) Inhibitory effects of autoantibodies on the muscarinic receptors in Sjogren's syndrome. *Lab Invest* 84:1430–1438
 76. Bacman S, Perez Leiros C, Sterin-Borda L, Hubscher O, Arana R, Borda E (1998) Autoantibodies against lacrimal gland M3 muscarinic acetylcholine receptors in patients with primary Sjogren's syndrome. *Invest Ophthalmol Vis Sci* 39:151–156
 77. Robinson CP, Brayer J, Yamachika S, Esch TR, Peck AB, Stewart CA, Peen E, Jonsson R, Humphreys-Beher MG (1998) Transfer of human serum IgG to nonobese diabetic Igmu null mice reveals a role for autoantibodies in the loss of secretory function of exocrine tissues in Sjogren's syndrome. *Proc Natl Acad Sci U S A* 95:7538–7543
 78. Cavill D, Waterman SA, Gordon TP (2004) Antibodies raised against the second extracellular loop of the human muscarinic M3 receptor mimic functional autoantibodies in Sjogren's syndrome. *Scand J Immunol* 59:261–266
 79. Wang F, Jackson MW, Maughan V, Cavill D, Smith AJ, Waterman SA, Gordon TP (2004) Passive transfer of Sjogren's syndrome IgG produces the pathophysiology of overactive bladder. *Arthritis Rheum* 50:3637–3645
 80. Cavill D, Waterman SA, Gordon TP (2003) Antiidiotypic antibodies neutralize autoantibodies that inhibit cholinergic neurotransmission. *Arthritis Rheum* 48:3597–3602
 81. Bacman SR, Berra A, Sterin-Borda L, Borda ES (1998) Human primary Sjogren's syndrome autoantibodies as mediators of nitric oxide release coupled to lacrimal gland muscarinic acetylcholine receptors. *Curr Eye Res* 17:1135–1142
 82. Bacman S, Berra A, Sterin-Borda L, Borda E (2001) Muscarinic acetylcholine receptor antibodies as a new marker of dry eye Sjogren syndrome. *Invest Ophthalmol Vis Sci* 42:321–327

83. Berra A, Sterin-Borda L, Bacman S, Borda E (2002) Role of salivary IgA in the pathogenesis of Sjogren syndrome. *Clin Immunol* 104:49–57
84. Dawson LJ, Allison HE, Stanbury J, Fitzgerald D, Smith PM (2004) Putative anti-muscarinic antibodies cannot be detected in patients with primary Sjogren's syndrome using conventional immunological approaches. *Rheumatology (Oxford)* 43:1488–1495
85. Gao J, Cha S, Jonsson R, Opalko J, Peck AB (2004) Detection of antitype 3 muscarinic acetylcholine receptor autoantibodies in the sera of Sjogren's syndrome patients by use of a transfected cell line assay. *Arthritis Rheum* 50:2615–2621
86. Marczinovits I, Kovacs L, Gyorgy A, Toth GK, Dorgai L, Molnar J, Pokorny G (2005) A peptide of human muscarinic acetylcholine receptor 3 is antigenic in primary Sjogren's syndrome. *J Autoimmun* 24:47–54
87. Kovacs L, Marczinovits I, Gyorgy A, Toth GK, Dorgai L, Pal J, Molnar J, Pokorny G (2005) Clinical associations of autoantibodies to human muscarinic acetylcholine receptor 3(213-228) in primary Sjogren's syndrome. *Rheumatology (Oxford)* 44:1021–1025
88. Nagaraju K, Cox A, Casciola-Rosen L, Rosen A (2001) Novel fragments of the Sjogren's syndrome autoantigens alpha-fodrin and type 3 muscarinic acetylcholine receptor generated during cytotoxic lymphocyte granule-induced cell death. *Arthritis Rheum* 44:2376–2386
89. Dawson L, Tobin A, Smith P, Gordon T (2005) Antimuscarinic antibodies in Sjogren's syndrome: where are we, and where are we going? *Arthritis Rheum* 52:2984–2995
90. Waterman SA, Gordon TP, Rischmueller M (2000) Inhibitory effects of muscarinic receptor autoantibodies on parasympathetic neurotransmission in Sjogren's syndrome. *Arthritis Rheum* 43:1647–1654
91. Bacman S, Sterin-Borda L, Camusso JJ, Arana R, Hubscher O, Borda E (1996) Circulating antibodies against rat parotid gland M3 muscarinic receptors in primary Sjogren's syndrome. *Clin Exp Immunol* 104:454–459
92. Pedersen AM, Dissing S, Fahrenkrug J, Hannibal J, Reibel J, Nauntofte B (2000) Innervation pattern and Ca²⁺ signalling in labial salivary glands of healthy individuals and patients with primary Sjogren's syndrome (pSS). *J Oral Pathol Med* 29:97–109
93. Dawson LJ, Field EA, Harmer AR, Smith PM (2001) Acetylcholine-evoked calcium mobilization and ion channel activation in human labial gland acinar cells from patients with primary Sjogren's syndrome. *Clin Exp Immunol* 124:480–485
94. Humphreys-Beher MG, Brayer J, Yamachika S, Peck AB, Jonsson R (1999) An alternative perspective to the immune response in autoimmune exocrinopathy: induction of functional quiescence rather than destructive autoaggression. *Scand J Immunol* 49:7–10
95. Fox PC, Speight PM (1996) Current concepts of autoimmune exocrinopathy: immunologic mechanisms in the salivary pathology of Sjogren's syndrome. *Crit Rev Oral Biol Med* 7:144–158
96. Walker J, Gordon T, Lester S, Downie-Doyle S, McEvoy D, Pile K, Waterman S, Rischmueller M (2003) Increased severity of lower urinary tract symptoms and daytime somnolence in primary Sjogren's syndrome. *J Rheumatol* 30:2406–2412
97. Leppilahi M, Tammela TL, Huhtala H, Kiihola P, Leppilahi K, Auvinen A (2003) Interstitial cystitis-like urinary symptoms among patients with Sjogren's syndrome: a population-based study in Finland. *Am J Med* 115:62–65
98. Rosztochy A, Kovacs L, Wittmann T, Lonovics J, Pokorny G (2001) Manometric assessment of impaired esophageal motor function in primary Sjogren's syndrome. *Clin Exp Rheumatol* 19:147–152
99. Kovacs L, Torok T, Bari F, Keri Z, Kovacs A, Makula E, Pokorny G (2000) Impaired microvascular response to cholinergic stimuli in primary Sjogren's syndrome. *Ann Rheum Dis* 59:48–53
100. Bachmeyer C, Zuber M, Dupont S, Blanche P, Dhote R, Mas JL (1997) Adie syndrome as the initial sign of primary Sjogren syndrome. *Am J Ophthalmol* 123:691–692
101. Tumiati B, Perazzoli F, Negro A, Pantaleoni M, Regolisti G (2000) Heart rate variability in patients with Sjogren's syndrome. *Clin Rheumatol* 19:477–480
102. Kaplan MM (1996) Primary biliary cirrhosis. *N Engl J Med* 335:1570–1580
103. Czaja AJ, Homburger HA (2001) Autoantibodies in liver disease. *Gastroenterology* 120:239–249
104. Skopouli FN, Barbatis C, Moutsopoulos HM (1994) Liver involvement in primary Sjogren's syndrome. *Br J Rheumatol* 33:745–748
105. Csepregi A, Szodoray P, Zeher M (2002) Do autoantibodies predict autoimmune liver disease in primary Sjogren's syndrome? Data of 180 patients upon a 5 year follow-up. *Scand J Immunol* 56:623–629
106. Waaler E (1940) On the occurrence of a factor in human serum activating the specific agglutination of sheep blood corpuscles. *Acta Pathol Microbiol Scand* 17:172–188
107. Pike RM, Sulkin SE, Coggeshall HC (1949) Serological reactions in rheumatoid arthritis. II. Concerning the nature of the factor in rheumatoid arthritis serum responsible for increased agglutination of sensitized sheep erythrocytes. *J Immunol* 63:448–463
108. Newkirk MM (2002) Rheumatoid factors: what do they tell us? *J Rheumatol* 29:2034–2040
109. Victor KD, Randen I, Thompson K, Forre O, Natvig JB, Fu SM, Capra JD (1991) Rheumatoid factors isolated from patients with autoimmune disorders are derived from germline genes distinct from those encoding the Wa, Po, and Bla cross-reactive idiotypes. *J Clin Invest* 87:1603–1613
110. Hogben DN, Devey ME (1986) Studies on rheumatoid factor: I. The effect of rheumatoid factor on the clearance of preformed immune complexes in mice. *Clin Exp Immunol* 66:648–653
111. Wolfe F, Cathey MA, Roberts FK (1991) The latex test revisited. Rheumatoid factor testing in 8,287 rheumatic disease patients. *Arthritis Rheum* 34:951–960
112. Pertovaara M, Pukkala E, Laippala P, Miettinen A, Pasternack A (2001) A longitudinal cohort study of Finnish patients with primary Sjogren's syndrome: clinical, immunological, and epidemiological aspects. *Ann Rheum Dis* 60:467–472
113. Ioannidis JP, Vassiliou VA, Moutsopoulos HM (2002) Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren's syndrome. *Arthritis Rheum* 46:741–747
114. Brouet JC, Clauvel JP, Danon F, Klein M, Seligmann M (1974) Biologic and clinical significance of cryoglobulins. A report of 86 cases. *Am J Med* 57:775–788
115. Ferri C, Mascia MT (2006) Cryoglobulinemic vasculitis. *Curr Opin Rheumatol* 18:54–63
116. Dammacco F, Sansonno D, Piccoli C, Tucci FA, Racanelli V (2001) The cryoglobulins: an overview. *Eur J Clin Invest* 31:628–638
117. Ohara T, Itoh Y, Itoh K (2000) Reevaluation of laboratory parameters in relation to histological findings in primary and secondary Sjogren's syndrome. *Intern Med* 39:457–463
118. Zulman J, Jaffe R, Talal N (1978) Evidence that the malignant lymphoma of Sjogren's syndrome is a monoclonal B-cell neoplasm. *N Engl J Med* 299:1215–1220
119. Skopouli FN, Dafni U, Ioannidis JP, Moutsopoulos HM (2000) Clinical evolution, and morbidity and mortality of primary Sjogren's syndrome. *Semin Arthritis Rheum* 29:296–304
120. Katsikis PD, Youinou PY, Galonopoulou V, Papadopoulos NM, Tzioufas AG, Moutsopoulos HM (1990) Monoclonal process in primary Sjogren's syndrome and cross-reactive idiotype associated with rheumatoid factor. *Clin Exp Immunol* 82:509–514
121. Martin T, Weber JC, Levallois H, Labouret N, Soley A, Koenig S, Korganow AS, Pasquali JL (2000) Salivary gland lymphomas in patients with Sjogren's syndrome may frequently develop from rheumatoid factor B cells. *Arthritis Rheum* 43:908–916

122. Mariette X (2001) Lymphomas complicating Sjogren's syndrome and hepatitis C virus infection may share a common pathogenesis: chronic stimulation of rheumatoid factor B cells. *Ann Rheum Dis* 60:1007–1010
123. Tzioufas AG, Boumba DS, Skopouli FN, Moutsopoulos HM (1996) Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjogren's syndrome. *Arthritis Rheum* 39:767–772
124. Zhou D, Ursitti JA, Bloch RJ (1998) Developmental expression of spectrins in rat skeletal muscle. *Mol Biol Cell* 9:47–61
125. Bennett V (1990) Spectrin-based membrane skeleton: a multi-potential adaptor between plasma membrane and cytoplasm. *Physiol Rev* 70:1029–1065
126. Perrin D, Aunis D (1985) Reorganization of alpha-fodrin induced by stimulation in secretory cells. *Nature* 315:589–592
127. Lukowski S, Lecomte MC, Mira JP, Marin P, Gautero H, Russo-Marie F, Geny B (1996) Inhibition of phospholipase D activity by fodrin. An active role for the cytoskeleton. *J Biol Chem* 271:24164–24171
128. Perrin D, Langley OK, Aunis D (1987) Anti-alpha-fodrin inhibits secretion from permeabilized chromaffin cells. *Nature* 326:498–501
129. Siman R, Baudry M, Lynch G (1985) Regulation of glutamate receptor binding by the cytoskeletal protein fodrin. *Nature* 313:225–228
130. Haneji N, Nakamura T, Takio K, Yanagi K, Higashiyama H, Saito I, Noji S, Sugino H, Hayashi Y (1997) Identification of alphafodrin as a candidate autoantigen in primary Sjogren's syndrome. *Science* 276:604–607
131. Watanabe T, Tsuchida T, Kanda N, Mori K, Hayashi Y, Tamaki K (1999) Anti-alpha-fodrin antibodies in Sjogren syndrome and lupus erythematosus. *Arch Dermatol* 135:535–539
132. Witte T, Matthias T, Arnett FC, Peter HH, Hartung K, Sachse C, Wigand R, Braner A, Kalden JR, Lakomek HJ, Schmidt RE (2000) IgA and IgG autoantibodies against alpha-fodrin as markers for Sjogren's syndrome. *Systemic lupus erythematosus. J Rheumatol* 27:2617–2620
133. Nordmark G, Rorsman F, Ronnblom L, Cajander S, Taussig MJ, Kampe O, Winqvist O (2003) Autoantibodies to alpha-fodrin in primary Sjogren's syndrome and SLE detected by an in vitro transcription and translation assay. *Clin Exp Rheumatol* 21:49–56
134. Ruiz-Tiscar JL, Lopez-Longo FJ, Sanchez-Ramon S, Santamaria B, Urrea R, Carreno L, Estechea A, Vigil D, Fernandez-Cruz E, Rodriguez-Mahou M (2005) Prevalence of IgG anti- α -fodrin antibodies in Sjogren's syndrome. *Ann N Y Acad Sci* 1050:210–216
135. Ulbricht KU, Schmidt RE, Witte T (2003) Antibodies against alpha-fodrin in Sjogren's syndrome. *Autoimmun Rev* 2:109–113
136. Ruffatti A, Ostuni P, Grypiotis P, Botsios C, Tonello M, Grava C, Favaro M, Todesco S (2004) Sensitivity and specificity for primary Sjogren's syndrome of IgA and IgG anti-alpha-fodrin antibodies detected by ELISA. *J Rheumatol* 31:504–507
137. Turkcapar N, Olmez U, Tutkak H, Duman M (2006) The importance of alpha-fodrin antibodies in the diagnosis of Sjogren's syndrome. *Rheumatol Int* 26:354–359
138. Zandbelt MM, Vogelzangs J, Van De Putte LB, Van Venrooij WJ, Van Den Hoogen FH (2004) Anti-alpha-fodrin antibodies do not add much to the diagnosis of Sjogren's syndrome. *Arthritis Res Ther* 6:R33–R38
139. Kuwana M, Okano T, Ogawa Y, Kaburaki J, Kawakami Y (2001) Autoantibodies to the amino-terminal fragment of beta-fodrin expressed in glandular epithelial cells in patients with Sjogren's syndrome. *J Immunol* 167:5449–5456
140. Vanags DM, Porn-Ares MI, Coppola S, Burgess DH, Orrenius S (1996) Protease involvement in fodrin cleavage and phosphatidylserine exposure in apoptosis. *J Biol Chem* 271:31075–31085
141. Saegusa K, Ishimaru N, Yanagi K, Mishima K, Arakaki R, Suda T, Saito I, Hayashi Y (2002) Prevention and induction of autoimmune exocrinopathy is dependent on pathogenic autoantigen cleavage in murine Sjogren's syndrome. *J Immunol* 169:1050–1057
142. Wang Y, Virji AS, Howard P, Sayani Y, Zhang J, Achu P, McArthur C (2006) Detection of cleaved alpha-fodrin autoantigen in Sjogren's syndrome: apoptosis and co-localisation of cleaved alphafodrin with activated caspase-3 and cleaved poly (ADP-ribose) polymerase (PARP) in labial salivary glands. *Arch Oral Biol* 51:558–566
143. Winer S, Astsaturov I, Cheung R, Tsui H, Song A, Gaedigk R, Winer D, Sampson A, McKerlie C, Bookman A, Dosch HM (2002) Primary Sjogren's syndrome and deficiency of ICA69. *Lancet* 360:1063–1069
144. Burkle A (2005) Poly(ADP-ribose). The most elaborate metabolite of NAD⁺. *Febs J* 272:4576–4589
145. de Murcia G, Menissier-de Murcia J, Schreiber V (1991) Poly(ADP-ribose) polymerase: molecular biological aspects. *Bioessays* 13:455–462
146. de Murcia G, Menissier-de Murcia J (1994) Poly(ADP-ribose) polymerase: a molecular nick-sensor. *Trends Biochem Sci* 19:172–176
147. Yamanaka H, Willis EH, Carson DA (1989) Human autoantibodies to poly(adenosine diphosphate-ribose) polymerase recognize cross-reactive epitopes associated with the catalytic site of the enzyme. *J Clin Invest* 83:180–186
148. Yamanaka H, Willis EH, Penning CA, Peebles CL, Tan EM, Carson DA (1987) Human autoantibodies to poly(adenosine diphosphate-ribose) polymerase. *J Clin Invest* 80:900–904
149. Negri C, Scovassi AI, Cerino A, Negroni M, Borzi RM, Meliconi R, Facchini A, Montecucco CM, Astaldi Ricotti GC (1990) Autoantibodies to poly(ADP-ribose)polymerase in autoimmune diseases. *Autoimmunity* 6:203–209
150. Muller S, Briand JP, Barakat S, Lagueux J, Poirier GG, de Murcia G, Isenberg DA (1994) Autoantibodies reacting with poly(ADP-ribose) and with a zinc-finger functional domain of poly(ADP-ribose) polymerase involved in the recognition of damaged DNA. *Clin Immunol Immunopathol* 73:187–196
151. Jimenez F, Aiba-Masago S, Al Hashimi I, Vela-Roch N, Fernandes G, Yeh CK, Talal N, Dang H (2002) Activated caspase 3 and cleaved poly(ADP-ribose)polymerase in salivary epithelium suggest a pathogenetic mechanism for Sjogren's syndrome. *Rheumatology (Oxford)* 41:338–342
152. Price CM, McCarty GA, Pettijohn DE (1984) NuMA protein is a human autoantigen. *Arthritis Rheum* 27:774–779
153. Andrade LE, Chan EK, Peebles CL, Tan EM (1996) Two major autoantigen-antibody systems of the mitotic spindle apparatus. *Arthritis Rheum* 39:1643–1653
154. Grypiotis P, Ruffatti A, Tonello M, Winzler C, Radu C, Zampieri S, Favaro M, Calligaro A, Todesco S (2002) Clinical significance of fluoroscopic patterns specific for the mitotic spindle in patients with rheumatic diseases. *Reumatismo* 54:232–237
155. Rodriguez JL, Gelpi C, Thomson TM, Real FJ, Fernandez J (1982) Anti-golgi complex autoantibodies in a patient with Sjogren syndrome and lymphoma. *Clin Exp Immunol* 49:579–586
156. Nozawa K, Fritzier MJ, von Muhlen CA, Chan EK (2004) Giantin is the major Golgi autoantigen in human anti-Golgi complex sera. *Arthritis Res Ther* 6:R95–R102
157. Chan EKL, Fritzier MJ (1998) Golgins: coiled-coil proteins associated with the Golgi complex. *Electronic J Biotechnol* 1:1–10
158. Griffith KJ, Chan EK, Lung CC, Hamel JC, Guo X, Miyachi K, Fritzier MJ (1997) Molecular cloning of a novel 97-kd Golgi complex autoantigen associated with Sjogren's syndrome. *Arthritis Rheum* 40:1693–1702

159. Fujii T, Mimori T, Akizuki M (1996) Detection of autoantibodies to nucleolar transcription factor NOR 90/hUBF in sera of patients with rheumatic diseases, by recombinant autoantigenbased assays. *Arthritis Rheum* 39:1313–1318
160. von Muhlen CA, Tan EM (1995) Autoantibodies in the diagnosis of systemic rheumatic diseases. *Semin Arthritis Rheum* 24:323–358
161. Imai H, Fritzler MJ, Neri R, Bombardieri S, Tan EM, Chan EK (1994) Immunocytochemical characterization of human NOR-90 (upstream binding factor) and associated antigens reactive with autoimmune sera. Two MR forms of NOR-90/hUBF autoantigens. *Mol Biol Rep* 19:115–124
162. Navone R, Lunardi C, Gerli R, Tinazzi E, Peterlana D, Bason C, Corrocher R, Puccetti A (2005) Identification of tear lipocalin as a novel autoantigen target in Sjogren's syndrome. *J Autoimmun* 25:229–234
163. Gachon AM, Lacazette E (1998) Tear lipocalin and the eye's front line of defence. *Br J Ophthalmol* 82:453–455
164. Redl B (2000) Human tear lipocalin. *Biochim Biophys Acta* 1482:241–248